The Multifaceted Biology of PCSK9

Buja, 2014, Nikolai N. Anitschkow and the lipid hypothesis of atherosclerosis, Cardiovasc Pathol., 23, 183, 10.1016/j.carpath.2013.12.004

Frantz, 1969, The sterol hypothesis in atherogenesis, Am J Med., 46, 684, 10.1016/0002-9343(69)90020-5

Endo, 2010, A historical perspective on the discovery of statins, Proc Jpn Acad Ser B Phys Biol Sci, 86, 484, 10.2183/pjab.86.484

Li, Triumph of the Heart: The Story of Statins., 10.1093/oso/9780195323573.001.0001

Jones, 1998, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study), Am J Cardiol., 81, 582, 10.1016/S0002-9149(97)00965-X

Shimano, 2001, Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes, Prog Lipid Res., 40, 439, 10.1016/S0163-7827(01)00010-8

Amemiya-Kudo, 2002, Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes, J Lipid Res., 43, 1220, 10.1194/jlr.M100417-JLR200

Goldstein, 2009, The LDL receptor, Arterioscler Thromb Vasc Biol., 29, 431, 10.1161/ATVBAHA.108.179564

Davignon, 2004, The cardioprotective effects of statins, Curr Atheroscler Rep., 6, 27, 10.1007/s11883-004-0113-7

Rosenblum, 1998, Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption, J Med Chem., 41, 973, 10.1021/jm970701f

Smith, 2015, Role of ezetimibe in lipid-lowering and cardiovascular disease prevention, Curr Atheroscler Rep., 17, 72, 10.1007/s11883-015-0550-5

Giugliano, 2018, Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial), Circulation., 137, 1571, 10.1161/CIRCULATIONAHA.117.030950

Schjoldager, 2012, Site-specific protein O-glycosylation modulates proprotein processing—deciphering specific functions of the large polypeptide GalNAc-transferase gene family, Biochim Biophys Acta, 1820, 2079, 10.1016/j.bbagen.2012.09.014

Schjoldager, 2020, Global view of human protein glycosylation pathways and functions, Nat Rev Mol Cell Biol., 21, 729, 10.1038/s41580-020-00294-x

Aebersold, 2018, How many human proteoforms are there?, Nat Chem Biol., 14, 206, 10.1038/nchembio.2576

Tagliabracci, 2015, A single kinase generates the majority of the secreted phosphoproteome, Cell., 161, 1619, 10.1016/j.cell.2015.05.028

Cui, 2015, A secretory kinase complex regulates extracellular protein phosphorylation, Elife., 4, e06120, 10.7554/eLife.06120

Neurath, 1989, Proteolytic processing and physiological regulation, Trends Biochem Sci., 14, 268, 10.1016/0968-0004(89)90061-3

Neurath, 1976, Role of proteolytic enzymes in biological regulation (a review), Proc Natl Acad Sci U S A., 73, 3825, 10.1073/pnas.73.11.3825

Lazure, 1983, Proteases and posttranslational processing of prohormones: a review, Can J Biochem Cell Biol., 61, 501, 10.1139/o83-066

Steiner, 1967, Insulin biosynthesis: evidence for a precursor, Science., 157, 697, 10.1126/science.157.3789.697

Steiner, 2011, On the discovery of precursor processing, Methods Mol Biol., 768, 3, 10.1007/978-1-61779-204-5_1

Chrétien, 1967, Isolation, purification, and characterization of gamma-lipotropic hormone from sheep pituitary glands, Can J Biochem., 45, 1163, 10.1139/o67-133

Chrétien, 1976, Isolation of peptides with opiate activity from sheep and human pituitaries: relationship to beta-lipotropin, Biochem Biophys Res Commun., 72, 472, 10.1016/S0006-291X(76)80066-6

Chrétien, 2013, How the prohormone theory solved two important controversies in hormonal and neural Peptide biosynthesis, Front Endocrinol (Lausanne)., 4, 148, 10.3389/fendo.2013.00148

Seidah, 1976, Letter: fragment of sheep beta-lipotropin with morphine-like activity, Lancet., 1, 1017, 10.1016/S0140-6736(76)91883-3

Seidah, 1999, Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides, Brain Res., 848, 45, 10.1016/S0006-8993(99)01909-5

Seidah, 2012, The biology and therapeutic targeting of the proprotein convertases, Nat Rev Drug Discov., 11, 367, 10.1038/nrd3699

Seidah, 2013, The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions, J Biol Chem., 288, 21473, 10.1074/jbc.R113.481549

Benjannet, 2006, The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J Biol Chem., 281, 30561, 10.1074/jbc.M606495200

Rawson, 1998, Isolation of cholesterol-requiring mutant Chinese hamster ovary cells with defects in cleavage of sterol regulatory element-binding proteins at site 1, J Biol Chem., 273, 28261, 10.1074/jbc.273.43.28261

Lenz, 2001, The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P, Proc Natl Acad Sci U S A., 98, 12701, 10.1073/pnas.221447598

Vincent, 2003, Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1, J Virol., 77, 8640, 10.1128/JVI.77.16.8640-8649.2003

Seidah, 1999, Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization, Proc Natl Acad Sci U S A., 96, 1321, 10.1073/pnas.96.4.1321

Sakai, 1998, Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells, Mol Cell., 2, 505, 10.1016/S1097-2765(00)80150-1

Ye, 2000, ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs, Mol Cell., 6, 1355, 10.1016/S1097-2765(00)00133-7

Seidah, 2012, Proprotein convertases SKI-1/S1P and PCSK9, Handbook of the Biologically Active Peptides, 1

Espenshade, 1999, Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins, J Biol Chem., 274, 22795, 10.1074/jbc.274.32.22795

Pullikotil, 2004, Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P: processing of SREBP-2, ATF6, and a viral glycoprotein, J Biol Chem., 279, 17338, 10.1074/jbc.M313764200

Pasquato, 2006, The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors, J Biol Chem., 281, 23471, 10.1074/jbc.M513675200

Seidah, 2002, Precursor convertases in the secretory pathway, cytosol and extracellular milieu, Essays Biochem., 38, 79, 10.1042/bse0380079

Seidah, 2007, The proprotein convertases are potential targets in the treatment of dyslipidemia, J Mol Med (Berl)., 85, 685, 10.1007/s00109-007-0172-7

Pasquato, 2018, Cleavage of the glycoprotein of arenaviruses, Activat Viruses Host Proteases, 47, 10.1007/978-3-319-75474-1_3

Velho, 2017, Site-1 protease and lysosomal homeostasis, Biochim Biophys Acta Mol Cell Res., 1864, 2162, 10.1016/j.bbamcr.2017.06.023

Tassew, 2012, SKI-1 and Furin generate multiple RGMa fragments that regulate axonal growth, Dev Cell., 22, 391, 10.1016/j.devcel.2011.11.022

Nakagawa, 2017, Site-1 protease is required for the generation of soluble (pro)renin receptor, J Biochem., 161, 369, 10.1093/jb/mvw080

Seidah, 2021, How do enveloped viruses exploit the secretory proprotein convertases to regulate infectivity and spread?, Viruses, 13, 1229, 10.3390/v13071229

Kondo, 2018, Site-1 protease deficiency causes human skeletal dysplasia due to defective inter-organelle protein trafficking, JCI Insight, 3, e121596, 10.1172/jci.insight.121596

Ye, 2020, Transcription factors activated through RIP (regulated intramembrane proteolysis) and RAT (regulated alternative translocation), J Biol Chem., 295, 10271, 10.1074/jbc.REV120.012669

Marschner, 2011, A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism, Science., 333, 87, 10.1126/science.1205677

Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc Natl Acad Sci U S A., 100, 928, 10.1073/pnas.0335507100

Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet., 34, 154, 10.1038/ng1161

Varret, 1999, A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32, Am J Hum Genet., 64, 1378, 10.1086/302370

Hunt, 2000, Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred, Arterioscler Thromb Vasc Biol., 20, 1089, 10.1161/01.ATV.20.4.1089

Naureckiene, 2003, Functional characterization of Narc 1, a novel proteinase related to proteinase K, Arch Biochem Biophys., 420, 55, 10.1016/j.abb.2003.09.011

Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J Biol Chem., 279, 48865, 10.1074/jbc.M409699200

Benjannet, 2012, Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation, J Biol Chem., 287, 33745, 10.1074/jbc.M112.399725

Saavedra, 2013, PCSK9 prosegment chimera as novel inhibitors of LDLR degradation, PLoS One., 8, e72113, 10.1371/journal.pone.0072113

Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat Struct Mol Biol., 14, 413, 10.1038/nsmb1235

Piper, 2007, The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol, Structure., 15, 545, 10.1016/j.str.2007.04.004

Roubtsova, 2011, Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue, Arterioscler Thromb Vasc Biol., 31, 785, 10.1161/ATVBAHA.110.220988

Maxwell, 2005, Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment, Proc Natl Acad Sci U S A, 102, 2069, 10.1073/pnas.0409736102

Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype, Proc Natl Acad Sci U S A., 101, 7100, 10.1073/pnas.0402133101

Park, 2004, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J Biol Chem., 279, 50630, 10.1074/jbc.M410077200

Maxwell, 2003, Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice, J Lipid Res., 44, 2109, 10.1194/jlr.M300203-JLR200

Horton, 2003, Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes, Proc Natl Acad Sci U S A., 100, 12027, 10.1073/pnas.1534923100

Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler Thromb Vasc Biol., 24, 1454, 10.1161/01.ATV.0000134621.14315.43

Attie, 2005, Dual regulation of the LDL receptor–some clarity and new questions, Cell Metab., 1, 290, 10.1016/j.cmet.2005.04.006

Timms, 2004, A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree, Hum Genet., 114, 349, 10.1007/s00439-003-1071-9

Cohen, 2005, Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9, Nat Genet., 37, 161, 10.1038/ng1509

Cohen, 2006, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med., 354, 1264, 10.1056/NEJMoa054013

Yang, 2001, Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene, Proc Natl Acad Sci U S A., 98, 13607, 10.1073/pnas.201524598

Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc Natl Acad Sci U S A., 102, 5374, 10.1073/pnas.0501652102

Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am J Hum Genet., 79, 514, 10.1086/507488

Hooper, 2007, The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population, Atherosclerosis., 193, 445, 10.1016/j.atherosclerosis.2006.08.039

McNutt, 2007, Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells, J Biol Chem., 282, 20799, 10.1074/jbc.C700095200

Poirier, 2008, The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2, J Biol Chem., 283, 2363, 10.1074/jbc.M708098200

Mayne, 2011, Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture, Clin Chem., 57, 1415, 10.1373/clinchem.2011.165191

Lebeau, 2021, The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury, J Clin Invest., 131, e128650, 10.1172/JCI128650

Lo Surdo, 2011, Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH, EMBO Rep., 12, 1300, 10.1038/embor.2011.205

Kwon, 2008, Molecular basis for LDL receptor recognition by PCSK9, Proc Natl Acad Sci U S A., 105, 1820, 10.1073/pnas.0712064105

Holla, 2011, Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor, Biochem Biophys Res Commun., 406, 234, 10.1016/j.bbrc.2011.02.023

Benjannet, 2010, Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events, J Biol Chem., 285, 40965, 10.1074/jbc.M110.154815

Seidah, 2019, The elusive inhibitory function of the acidic N-terminal segment of the prodomain of PCSK9: the plot thickens, J Mol Biol., 431, 904, 10.1016/j.jmb.2019.01.015

Berge, 2006, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy, Arterioscler Thromb Vasc Biol., 26, 1094, 10.1161/01.ATV.0000204337.81286.1c

Ben Djoudi Ouadda, 2019, Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (family with sequence similarity 20, Member C) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor), Arterioscler Thromb Vasc Biol., 39, 1996, 10.1161/ATVBAHA.119.313247

Nassoury, 2007, The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR, Traffic., 8, 718, 10.1111/j.1600-0854.2007.00562.x

Qian, 2007, Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis, J Lipid Res., 48, 1488, 10.1194/jlr.M700071-JLR200

Holla, 2007, Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly, BMC Cell Biol., 8, 9, 10.1186/1471-2121-8-9

Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J Clin Invest., 116, 2995, 10.1172/JCI29383

Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J Biol Chem., 282, 18602, 10.1074/jbc.M702027200

Poirier, 2009, Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route, J Biol Chem., 284, 28856, 10.1074/jbc.M109.037085

Susan-Resiga, 2017, The proprotein convertase subtilisin/kexin type 9-resistant R410S low density lipoprotein receptor mutation: a novel mechanism causing familial hypercholesterolemia, J Biol Chem., 292, 1573, 10.1074/jbc.M116.769430

Mikaeeli, 2020, Functional analysis of natural PCSK9 mutants in modern and archaic humans, FEBS J., 287, 515, 10.1111/febs.15036

Seidah, 2017, The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin/kexin 9, Pharmacol Rev., 69, 33, 10.1124/pr.116.012989

Seidah, 2014, PCSK9: a key modulator of cardiovascular health, Circ Res., 114, 1022, 10.1161/CIRCRESAHA.114.301621

Garçon, 2020, Circulating rather than intestinal PCSK9 (proprotein convertase subtilisin kexin type 9) regulates postprandial lipemia in mice, Arterioscler Thromb Vasc Biol., 40, 2084, 10.1161/ATVBAHA.120.314194

Peyot, 2021, Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice, Biochim Biophys Acta Mol Cell Biol Lipids., 1866, 158968, 10.1016/j.bbalip.2021.158968

Ramin-Mangata, 2021, Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function, Atherosclerosis., 326, 47, 10.1016/j.atherosclerosis.2021.03.044

Alborn, 2007, Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol, Clin Chem., 53, 1814, 10.1373/clinchem.2007.091280

Mayne, 2007, Plasma PCSK9 levels correlate with cholesterol in men but not in women, Biochem Biophys Res Commun., 361, 451, 10.1016/j.bbrc.2007.07.029

Lambert, 2008, Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment, Clin Chem., 54, 1038, 10.1373/clinchem.2007.099747

Lakoski, 2009, Genetic and metabolic determinants of plasma PCSK9 levels, J Clin Endocrinol Metab., 94, 2537, 10.1210/jc.2009-0141

Dubuc, 2010, A new method for measurement of total plasma PCSK9: clinical applications, J Lipid Res., 51, 140, 10.1194/jlr.M900273-JLR200

Awan, 2012, Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial, Clin Chem., 58, 183, 10.1373/clinchem.2011.172932

Allard, 2005, Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia, Hum Mutat., 26, 497, 10.1002/humu.9383

Cameron, 2006, Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, Hum Mol Genet., 15, 1551, 10.1093/hmg/ddl077

Essalmani, 2011, In vivo evidence that furin from hepatocytes inactivates PCSK9, J Biol Chem., 286, 4257, 10.1074/jbc.M110.192104

Bottomley, 2009, Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants, J Biol Chem., 284, 1313, 10.1074/jbc.M808363200

McNutt, 2009, Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells, J Biol Chem., 284, 10561, 10.1074/jbc.M808802200

Hampton, 2007, The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain, Proc Natl Acad Sci U S A., 104, 14604, 10.1073/pnas.0703402104

Filková, 2009, The role of resistin as a regulator of inflammation: Implications for various human pathologies, Clin Immunol., 133, 157, 10.1016/j.clim.2009.07.013

Dron, 2017, Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants, Curr Opin Lipidol., 28, 161, 10.1097/MOL.0000000000000386

Elbitar, 2018, New sequencing technologies help revealing unexpected mutations in autosomal dominant hypercholesterolemia, Sci Rep., 8, 1943, 10.1038/s41598-018-20281-9

Kotowski, 2006, A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol, Am J Hum Genet., 78, 410, 10.1086/500615

Cariou, 2009, PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia, Arterioscler Thromb Vasc Biol., 29, 2191, 10.1161/ATVBAHA.109.194191

Abifadel, 2009, Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease, Hum Mutat., 30, 520, 10.1002/humu.20882

Iacocca, 2018, Whole-gene duplication of PCSK9 as a novel genetic mechanism for severe familial hypercholesterolemia, Can J Cardiol., 34, 1316, 10.1016/j.cjca.2018.07.479

Poirier, 2015, GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation, Cell Rep., 13, 2064, 10.1016/j.celrep.2015.11.006

Zhu, 2015, Role of the unfolded protein response, GRP78 and GRP94 in organ homeostasis, J Cell Physiol., 230, 1413, 10.1002/jcp.24923

Gupta, 2016, GRP78 interacting partner Bag5 responds to ER stress and protects cardiomyocytes from ER stress-induced apoptosis, J Cell Biochem., 117, 1813, 10.1002/jcb.25481

Lin, 2017, GALNT6 stabilizes GRP78 protein by O-glycosylation and enhances its activity to suppress apoptosis under stress condition, Neoplasia., 19, 43, 10.1016/j.neo.2016.11.007

Abifadel, 2012, Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia, Atherosclerosis., 223, 394, 10.1016/j.atherosclerosis.2012.04.006

Horton, 2009, PCSK9: a convertase that coordinates LDL catabolism, J Lipid Res., 50(Suppl), S172, 10.1194/jlr.R800091-JLR200

Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor, Proc Natl Acad Sci U S A., 105, 13045, 10.1073/pnas.0806312105

Holla, 2011, Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors, J Lipid Res., 52, 1787, 10.1194/jlr.M018093

Ni, 2010, A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake, J Biol Chem., 285, 12882, 10.1074/jbc.M110.113035

Fasano, 2009, Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells, Atherosclerosis., 203, 166, 10.1016/j.atherosclerosis.2008.10.027

Strøm, 2010, Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain, Mol Genet Metab., 101, 76, 10.1016/j.ymgme.2010.05.003

Tveten, 2012, Characterization of a naturally occurring degradation product of the LDL receptor, Mol Genet Metab., 105, 149, 10.1016/j.ymgme.2011.10.008

Canuel, 2013, Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1), PLoS One., 8, e64145, 10.1371/journal.pone.0064145

Schiele, 2014, An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo, J Mol Biol., 426, 843, 10.1016/j.jmb.2013.11.011

Weider, 2016, Proprotein convertase subtilisin/kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation, J Biol Chem., 291, 16659, 10.1074/jbc.M116.717736

Essalmani, 2018, A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice, Biol Chem., 399, 1363, 10.1515/hsz-2018-0194

Butkinaree, 2015, Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9 convertase-mediated low density lipoprotein receptor degradation but interact with each other, J Biol Chem., 290, 18609, 10.1074/jbc.M115.647180

Poirier, 2016, Trafficking dynamics of PCSK9-induced LDLR degradation: focus on human PCSK9 mutations and C-terminal domain, PLoS One., 11, e0157230, 10.1371/journal.pone.0157230

Galvan, 2019, Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake, J Lipid Res., 60, 71, 10.1194/jlr.M087189

Jang, 2020, Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9, Eur Heart J., 41, 239, 10.1093/eurheartj/ehz566

Kim, 2018, Unconventional protein secretion - new insights into the pathogenesis and therapeutic targets of human diseases, J Cell Sci., 131, jcs213686, 10.1242/jcs.213686

Mayer, 2008, Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels, J Biol Chem., 283, 31791, 10.1074/jbc.M805971200

Saavedra, 2012, The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway, J Biol Chem., 287, 43492, 10.1074/jbc.M112.394023

Seidah, 2017, Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol, Nat Struct Mol Biol., 24, 785, 10.1038/nsmb.3471

Zaid, 2008, Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration, Hepatology., 48, 646, 10.1002/hep.22354

Rousselet, 2011, PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke, J Lipid Res., 52, 1383, 10.1194/jlr.M014118

Poirier, 2006, Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system, J Neurochem., 98, 838, 10.1111/j.1471-4159.2006.03928.x

Jacome Sanz, 2021, Proprotein convertase subtilisin/kexin type 9 regulates the production of acute-phase reactants from the liver, Liver Int., 41, 2511, 10.1111/liv.14993

Liu, 2010, PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain, J Lipid Res., 51, 2611, 10.1194/jlr.M006635

Parker, 2013, Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression, J Lipid Res., 54, 2400, 10.1194/jlr.M038331

Roubtsova, 2015, PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice, J Lipid Res., 56, 2133, 10.1194/jlr.M061952

Costet, 2006, Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c, J Biol Chem., 281, 6211, 10.1074/jbc.M508582200

Demers, 2015, PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver, Arterioscler Thromb Vasc Biol., 35, 2517, 10.1161/ATVBAHA.115.306032

Herbert, 2010, Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control, Arterioscler Thromb Vasc Biol., 30, 1333, 10.1161/ATVBAHA.110.204040

Bjørklund, 2014, Induction of atherosclerosis in mice and hamsters without germline genetic engineering, Circ Res., 114, 1684, 10.1161/CIRCRESAHA.114.302937

Denis, 2012, Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice, Circulation., 125, 894, 10.1161/CIRCULATIONAHA.111.057406

Tang, 2017, New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway, Atherosclerosis., 262, 113, 10.1016/j.atherosclerosis.2017.04.023

Mehta, 2006, Oxidized or native low-density lipoprotein cholesterol: which is more important in atherogenesis?, J Am Coll Cardiol., 48, 980, 10.1016/j.jacc.2006.06.001

Ding, 2020, PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1, Cardiovasc Res., 116, 908, 10.1093/cvr/cvz313

Landlinger, 2017, The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice, Eur Heart J., 38, 2499, 10.1093/eurheartj/ehx260

Ding, 2018, PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages, Cardiovasc Res., 114, 1145, 10.1093/cvr/cvy079

Langhi, 2009, PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion, Biochem Biophys Res Commun., 390, 1288, 10.1016/j.bbrc.2009.10.138

The Tabula Muris Consortium, 2018, Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris, Nature, 562, 367, 10.1038/s41586-018-0590-4

Mach, 2020, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J., 41, 111, 10.1093/eurheartj/ehz455

Seidah, 2019, Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies, Cardiovasc Res., 115, 510, 10.1093/cvr/cvz003

Tombling, 2021, The emerging landscape of peptide-based inhibitors of PCSK9, Atherosclerosis., 330, 52, 10.1016/j.atherosclerosis.2021.06.903

Fitzgerald, 2017, A highly durable RNAi therapeutic inhibitor of PCSK9, N Engl J Med., 376, 41, 10.1056/NEJMoa1609243

Catapano, 2020, New pharmacological approaches to target PCSK9, Curr Atheroscler Rep., 22, 24, 10.1007/s11883-020-00847-7

Xu, 2021, Three musketeers for lowering cholesterol: statins, ezetimibe and evolocumab, Curr Med Chem., 28, 1025, 10.2174/0929867327666200505091738

Nambi, 2021, Inclisiran: a game changer in a changing game?, J Am Coll Cardiol., 77, 1194, 10.1016/j.jacc.2021.01.008

Voutyritsa, 2021, PCSK9 antibody-based treatment strategies for patients with statin intolerance, In Vivo., 35, 61, 10.21873/invivo.12232

Hardy, 2021, A critical review of the efficacy and safety of inclisiran, Am J Cardiovasc Drugs, 10.1007/s40256-021-00477-7

Katzmann, 2020, PCSK9 inhibition: insights from clinical trials and future prospects, Front Physiol., 11, 595819, 10.3389/fphys.2020.595819

Ruscica, 2021, Lipid lowering drugs: present status and future developments, Curr Atheroscler Rep., 23, 17, 10.1007/s11883-021-00918-3

Guedeney, 2021, Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis, Eur Heart J Cardiovasc Pharmacother., 7, 225, 10.1093/ehjcvp/pvaa024

Kosmas, 2021, Inclisiran in dyslipidemia, Drugs Today (Barc)., 57, 311, 10.1358/dot.2021.57.5.3277083

Stein, 2014, Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9, Annu Rev Med., 65, 417, 10.1146/annurev-med-022613-090402

Chan, 2009, A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, Proc Natl Acad Sci U S A., 106, 9820, 10.1073/pnas.0903849106

Koren, 2014, Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab, J Am Coll Cardiol., 63, 2531, 10.1016/j.jacc.2014.03.018

Roth, 2014, Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial, Int J Cardiol., 176, 55, 10.1016/j.ijcard.2014.06.049

Benhuri, 2021, PCSK9 Inhibitors and ezetimibe monotherapy in patients not receiving statins: a meta-analysis of randomized trials, Curr Vasc Pharmacol., 19, 390, 10.2174/1570161118666200807114559

Gouni-Berthold, 2016, Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia, Br J Clin Pharmacol., 82, 1412, 10.1111/bcp.13066

Ito, 2017, PCSK9 inhibition with monoclonal antibodies-modern management of hypercholesterolemia, J Clin Pharmacol., 57, 7, 10.1002/jcph.766

Rey, 2016, Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid-lowering strategies, J Am Heart Assoc., 5, e003323, 10.1161/JAHA.116.003323

Silbernagel, 2019, The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption, J Lipid Res., 60, 161, 10.1194/jlr.P088583

Ginsberg, 2019, Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia, Cardiovasc Drugs Ther., 33, 69, 10.1007/s10557-019-06852-6

Kastelein, 2017, Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia, J Clin Lipidol., 11, 195, 10.1016/j.jacl.2016.12.004

Thedrez, 2018, Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab, Arterioscler Thromb Vasc Biol., 38, 592, 10.1161/ATVBAHA.117.310217

Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med., 376, 1713, 10.1056/NEJMoa1615664

Sabatine, 2017, Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, Lancet Diabetes Endocrinol., 5, 941, 10.1016/S2213-8587(17)30313-3

Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med., 379, 2097, 10.1056/NEJMoa1801174

Wiviott, 2020, Effect of evolocumab on type and size of subsequent myocardial infarction: a prespecified analysis of the FOURIER randomized clinical trial, JAMA Cardiol., 5, 787, 10.1001/jamacardio.2020.0764

Deedwania, 2021, Efficacy and Safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial, JAMA Cardiol., 6, 139, 10.1001/jamacardio.2020.3151

Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA., 302, 412, 10.1001/jama.2009.1063

Boffa, 2018, The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?, Curr Opin Lipidol., 29, 259, 10.1097/MOL.0000000000000499

Romagnuolo, 2015, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor, J Biol Chem., 290, 11649, 10.1074/jbc.M114.611988

Romagnuolo, 2017, Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by PCSK9, PLoS One., 12, e0180869, 10.1371/journal.pone.0180869

Blanchard, 2021, The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors, Cardiovasc Res., cvab247, 10.1093/cvr/cvab247

Villard, 2016, PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab, JACC Basic Transl Sci., 1, 419, 10.1016/j.jacbts.2016.06.006

Jukema, 2019, Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial, J Am Coll Cardiol., 74, 1167, 10.1016/j.jacc.2019.03.013

Tanowitz, 2017, Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes, Nucleic Acids Res., 45, 12388, 10.1093/nar/gkx960

Susan-Resiga, 2021, Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin, J Biol Chem., 297, 101177, 10.1016/j.jbc.2021.101177

Blais, 2021, Trends in lipid-modifying agent use in 83 countries, Atherosclerosis., 328, 44, 10.1016/j.atherosclerosis.2021.05.016

Dayoub, 2021, Adoption of PCSK9 inhibitors among patients with atherosclerotic disease, J Am Heart Assoc., 10, e019331, 10.1161/JAHA.120.019331

Grundy, 2019, 2018 Cholesterol clinical practice guidelines: synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety cholesterol guideline, Ann Intern Med., 170, 779, 10.7326/M19-0365

Crossey, 2015, A cholesterol-lowering VLP vaccine that targets PCSK9, Vaccine., 33, 5747, 10.1016/j.vaccine.2015.09.044

Pan, 2017, A therapeutic peptide vaccine against PCSK9, Sci Rep., 7, 12534, 10.1038/s41598-017-13069-w

Toth, 2020, Vaccines targeting PSCK9 for the treatment of hyperlipidemia, Cardiol Ther., 9, 323, 10.1007/s40119-020-00191-6

Fougeroux, 2021, Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity, Nat Commun., 12, 324, 10.1038/s41467-020-20251-8

Jinek, 2012, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science., 337, 816, 10.1126/science.1225829

Nidhi, 2021, Novel CRISPR-cas systems: an updated review of the current achievements, applications, and future research perspectives, Int J Mol Sci., 22, 3327, 10.3390/ijms22073327

Collins, 2021, Human molecular genetics and genomics—important advances and exciting possibilities, N Engl J Med., 384, 1, 10.1056/NEJMp2030694

Broeders, 2020, Sharpening the molecular scissors: advances in gene-editing technology, Iscience., 23, 100789, 10.1016/j.isci.2019.100789

Ding, 2014, Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing, Circ Res., 115, 488, 10.1161/CIRCRESAHA.115.304351

Rossidis, 2018, In utero CRISPR-mediated therapeutic editing of metabolic genes, Nat Med., 24, 1513, 10.1038/s41591-018-0184-6

Sun, 2020, CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation, Sci Adv., 6, eaba2983, 10.1126/sciadv.aba2983

Wei, 2020, Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing, Nat Commun., 11, 3232, 10.1038/s41467-020-17029-3

Musunuru, 2021, In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates, Nature., 593, 429, 10.1038/s41586-021-03534-y

Singer, 2016, The Third International Consensus definitions for sepsis and septic shock (sepsis-3), JAMA., 315, 801, 10.1001/jama.2016.0287

Russell, 2006, Management of sepsis, N Engl J Med., 355, 1699, 10.1056/NEJMra043632

Walley, 2014, PCSK9 is a critical regulator of the innate immune response and septic shock outcome, Sci Transl Med., 6, 258ra143, 10.1126/scitranslmed.3008782

Boyd, 2016, Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis, J Innate Immun., 8, 211, 10.1159/000442976

Walley, 2016, Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis, Curr Opin Crit Care., 22, 464, 10.1097/MCC.0000000000000351

Dwivedi, 2016, Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis, Shock., 46, 672, 10.1097/SHK.0000000000000682

Grin, 2018, Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor, Sci Rep., 8, 10496, 10.1038/s41598-018-28777-0

Yuan, 2020, PCSK9: a potential therapeutic target for sepsis, J Immunol Res., 2020, 2687692, 10.1155/2020/2687692

Leung, 2019, Reduced Proprotein convertase subtilisin/kexin 9 (PCSK9) function increases lipoteichoic acid clearance and improves outcomes in Gram positive septic shock patients, Sci Rep., 9, 10588, 10.1038/s41598-019-46745-0

Feng, 2019, A genetic approach to the association between PCSK9 and sepsis, JAMA Netw Open., 2, e1911130, 10.1001/jamanetworkopen.2019.11130

Genga, 2018, Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors, Ebiomedicine., 38, 257, 10.1016/j.ebiom.2018.11.032

Shimada, 2020, Very low density lipoprotein receptor sequesters lipopolysaccharide into adipose tissue during sepsis, Crit Care Med., 48, 41, 10.1097/CCM.0000000000004064

Efron, 2015, The future of murine sepsis and trauma research models, J Leukoc Biol., 98, 945, 10.1189/jlb.5MR0315-127R

Shaler, 2017, MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: defining a novel mechanism of superantigen-induced immunopathology and immunosuppression, PLoS Biol., 15, e2001930, 10.1371/journal.pbio.2001930

Laudanski, 2021, Humanized mice as a tool to study sepsis—more than meets the eye, Int J Mol Sci., 22, 2403, 10.3390/ijms22052403

Atreya, 2020, Proprotein convertase subtilisin/kexin type 9 loss-of-function is detrimental to the juvenile host with septic shock, Crit Care Med., 48, 1513, 10.1097/CCM.0000000000004487

Vecchié, 2021, PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study, J Intern Med., 289, 179, 10.1111/joim.13150

Innocenti, 2021, Plasma PCSK9 levels and sepsis severity: an early assessment in the emergency department, Clin Exp Med., 21, 101, 10.1007/s10238-020-00658-9

Rannikko, 2019, Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality, J Intern Med., 286, 553, 10.1111/joim.12946

Trinder, 2019, Molecular regulation of plasma lipid levels during systemic inflammation and sepsis, Curr Opin Lipidol., 30, 108, 10.1097/MOL.0000000000000577

Molina, 2007, The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus, J Hepatol., 46, 411, 10.1016/j.jhep.2006.09.024

Felmlee, 2013, Hepatitis C virus, cholesterol and lipoproteins–impact for the viral life cycle and pathogenesis of liver disease, Viruses., 5, 1292, 10.3390/v5051292

Caron, 2019, Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection, Stem Cell Res Ther., 10, 221, 10.1186/s13287-019-1342-6

D’Ambrosio, 2019, Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C, J Hepatol., 70, 379, 10.1016/j.jhep.2018.11.011

Hyrina, 2017, Treatment-induced viral cure of hepatitis C virus-infected patients involves a dynamic interplay among three important molecular players in lipid homeostasis: circulating microRNA (miR)-24, miR-223, and proprotein convertase subtilisin/kexin type 9, Ebiomedicine., 23, 68, 10.1016/j.ebiom.2017.08.020

Bridge, 2015, PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism, J Hepatol., 62, 763, 10.1016/j.jhep.2014.11.016

Grimm, 2021, Rapid decline of serum proprotein convertase subtilisin/kexin 9 (PCSK9) in non-cirrhotic patients with chronic hepatitis C infection receiving direct-acting antiviral therapy, J Clin Med., 10, 1621, 10.3390/jcm10081621

Labonté, 2009, PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression, Hepatology., 50, 17, 10.1002/hep.22911

Seidah, 2016, New developments in proprotein convertase subtilisin-kexin 9’s biology and clinical implications, Curr Opin Lipidol., 27, 274, 10.1097/MOL.0000000000000295

Bhatt, 2013, The global distribution and burden of dengue, Nature., 496, 504, 10.1038/nature12060

Gan, 2020, Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes, J Clin Invest., 130, 5223, 10.1172/JCI137536

Brown, 1997, The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor, Cell., 89, 331, 10.1016/S0092-8674(00)80213-5

Li, 2018, Proprotein convertase subtilisin/kexin type 9 inhibits interferon β expression through interacting with ATF-2, FEBS Lett., 592, 2323, 10.1002/1873-3468.13152

Tikoo, 2015, Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications, Biochem Pharmacol., 93, 343, 10.1016/j.bcp.2014.11.013

Shin, 2017, The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts, Heart Vessels., 32, 618, 10.1007/s00380-016-0936-5

Zhang, 2020, In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19, Cell Metab., 32, 176, 10.1016/j.cmet.2020.06.015

Tan, 2020, Statin use is associated with lower disease severity in COVID-19 infection, Sci Rep., 10, 17458, 10.1038/s41598-020-74492-0

Memel, 2021, Statins are associated with improved 28-day mortality in patients hospitalized with SARS-CoV-2 Infection, medRxiv

Vuorio, 2020, Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia, J Clin Lipidol., 14, 617, 10.1016/j.jacl.2020.06.006

Vuorio, 2021, PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia, J Intern Med., 289, 749, 10.1111/joim.13210

Zhang, 2020, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science., eabd4570

Gudleski-O’Regan, 2012, Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity, Cell Host Microbe., 12, 86, 10.1016/j.chom.2012.05.012

Mayengbam, 2021, Influence of cholesterol on cancer progression and therapy, Transl Oncol., 14, 101043, 10.1016/j.tranon.2021.101043

Cruz, 2013, The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics, Front Pharmacol., 4, 119, 10.3389/fphar.2013.00119

Vasseur, 2016, LDL Receptor: An open route to feed pancreatic tumor cells, Mol Cell Oncol., 3, e1033586, 10.1080/23723556.2015.1033586

Guillaumond, 2015, Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma, Proc Natl Acad Sci U S A., 112, 2473, 10.1073/pnas.1421601112

Goldstein, 1990, Regulation of the mevalonate pathway, Nature., 343, 425, 10.1038/343425a0

Schafer, 1989, Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans, Science., 245, 379, 10.1126/science.2569235

Wesierska-Gadek, 2008, A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744 832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy, J Cell Biochem., 104, 189, 10.1002/jcb.21612

Liu, 2020, Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer, Nature., 588, 693, 10.1038/s41586-020-2911-7

Almeida, 2021, Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy, Signal Transduct Target Ther., 6, 111, 10.1038/s41392-021-00530-6

Gangloff, 2017, Can iPCSK9-induced hypocholesterolemia starve cancer cells?, J Clin Lipidol., 11, 600, 10.1016/j.jacl.2017.04.001

Sun, 2012, Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver, Neoplasia., 14, 1122, 10.1593/neo.121252

Nowak, 2018, A Mendelian randomization study of the effects of blood lipids on breast cancer risk, Nat Commun., 9, 3957, 10.1038/s41467-018-06467-9

Bhattacharya, 2021, Proprotein convertase subtilisin/kexin type 9 (PCSK9): a potential multifaceted player in cancer, Biochim Biophys Acta Rev Cancer., 1876, 188581, 10.1016/j.bbcan.2021.188581

Yuan, 2021, Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling, Protein Cell., 12, 240, 10.1007/s13238-021-00821-2

Voutsadakis, 2016, Immune blockade inhibition in breast cancer, Anticancer Res., 36, 5607, 10.21873/anticanres.11145

Park, 2016, Immune checkpoint inhibitors for cancer treatment, Arch Pharm Res., 39, 1577, 10.1007/s12272-016-0850-5

Han, 2014, Isolation and characterization of the circulating truncated form of PCSK9, J Lipid Res., 55, 1505, 10.1194/jlr.M049346

Demetz, 2020, The haemochromatosis gene Hfe and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis development, Eur Heart J., 41, 3949, 10.1093/eurheartj/ehaa140

Robert, 2020, A decade of immune-checkpoint inhibitors in cancer therapy, Nat Commun., 11, 3801, 10.1038/s41467-020-17670-y

Liang, 2012, Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates, J Pharmacol Exp Ther., 340, 228, 10.1124/jpet.111.187419

Liu, 2019, The immune functions of PCSK9: Local and systemic perspectives, J Cell Physiol., 234, 19180, 10.1002/jcp.28612

Mestas, 2004, Of mice and not men: differences between mouse and human immunology, J Immunol., 172, 2731, 10.4049/jimmunol.172.5.2731

Jin, 2021, Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: a comprehensive review, Cancer Sci., 112, 2592, 10.1111/cas.14934

Korneva, 2021, The state of the problem of achieving extremely low LDL levels, Curr Pharm Des., 10.2174/1381612827999210111182030

Conroy, 2018, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med., 379, 2395, 10.1056/NEJMoa1809775

Seidah, 2017, The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol, J Glob Cardiol Sci Pract., 2017, e201702

Mikaeeli, 2020, Functional analysis of natural PCSK9 Mutants in modern and archaic humans, FEBS J., 287, 515, 10.1111/febs.15036

Ding, 2007, Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species, PLoS One., 2, e1098, 10.1371/journal.pone.0001098

Cameron, 2008, Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion, FEBS J., 275, 4121, 10.1111/j.1742-4658.2008.06553.x

Murphy, 2001, Molecular phylogenetics and the origins of placental mammals, Nature., 409, 614, 10.1038/35054550

van Asch, 2021, Patterns and tempo of PCSK9 pseudogenizations suggest an ancient divergence in mammalian cholesterol homeostasis mechanisms, Genetica., 149, 1, 10.1007/s10709-021-00113-x

Poulsen, 2018, Plaque burden influences accurate classification of fibrous cap atheroma by in vivo optical coherence tomography in a porcine model of advanced coronary atherosclerosis, Eurointervention., 14, 1129, 10.4244/EIJ-D-17-01028